Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2001

View Archived Issues

Pharmacological profile of potential new antidepressant, S-33005, described in detail

New DNA vaccine provides both tumor-specific immunity and antiangiogenesis

Antiproliferative effects of nitrosulindac demonstrated against human colon cancer cells

E-6259, Esteve's new antiarthritic agent, significantly more potent than celecoxib

Therapeutic benefits demonstrated for dual H1 antagonist/5-LO inhibitor in asthma models

Inhibitor of p38 kinase advances to clinical testing at Roche Bioscience

Orally active IKK2 inhibitor characterized at Inflammation 2001

Clinical candidate p38 MAP kinase inhibitor selected by Boehringer Ingelheim

Novel sickle cell disease therapy demonstrates favorable PK/PD profile in humans

Blood pressure response to eplerenone not related to plasma renin or serum aldosterone levels

Oral liquid formulation of DPC-423 better than tablets according to pharmacokinetic analysis

Final phase I/II clinical data presented at European psoriasis meeting for siplizumab

Selective inhibitor of IL-5 AWD-72-001 may have potential in allergic diseases

Thalidomide-derived compounds inhibit lung inflammation in mice

Neuropsychometric testing with PD-216948 reveals no clinically relevant effects

Pharmacokinetic/pharmacodynamic studies support further development of insulin Spiros

Glycopeptides from Advanced Medicine active against resistant Gram-positive pathogens

Modified doxorubicins and daunorubicins suitable for use in immunoconjugates

New anti-HIV agents with low cytotoxicity

Pyrrole and pyrrolidine derivatives as PDE4 and TNF production inhibitors

AstraZeneca presents new antiarrhythmic agents with class III activity

Orally active antiinflammatory agents from Pharmacia selectively inhibit COX-2

Thyroid hormone receptor modulator commences human safety trials

Postponement of 41st ICAAC meeting until December

WX-UK1: the first urokinase inhibitor to enter clinical trials

sBLA submitted for ARANESP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...